153 related articles for article (PubMed ID: 37280463)
1. Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data.
Garafola S; Shiferaw E; Dev V
Drugs Real World Outcomes; 2023 Sep; 10(3):351-356. PubMed ID: 37280463
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).
Zhang M; Xie W; Li J; Zheng J; Zhou Y
Arch Womens Ment Health; 2024 Feb; 27(1):35-44. PubMed ID: 37831172
[TBL] [Abstract][Full Text] [Related]
3. Brexanolone for postpartum depression.
Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
[TBL] [Abstract][Full Text] [Related]
4. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
Leader LD; O'Connell M; VandenBerg A
Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
[TBL] [Abstract][Full Text] [Related]
5. Brexanolone for the treatment of patients with postpartum depression.
Morrison KE; Cole AB; Thompson SM; Bale TL
Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571
[TBL] [Abstract][Full Text] [Related]
6. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
Powell JG; Garland S; Preston K; Piszczatoski C
Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
[No Abstract] [Full Text] [Related]
7. Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.
Patatanian E; Nguyen DR
J Pharm Pract; 2022 Jun; 35(3):431-436. PubMed ID: 33302791
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
[TBL] [Abstract][Full Text] [Related]
9. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
10. Brexanolone to Treat Postpartum Depression in Adult Women.
Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
[TBL] [Abstract][Full Text] [Related]
11. Brexanolone, a GABA
Edinoff AN; Odisho AS; Lewis K; Kaskas A; Hunt G; Cornett EM; Kaye AD; Kaye A; Morgan J; Barrilleaux PS; Lewis D; Viswanath O; Urits I
Front Psychiatry; 2021; 12():699740. PubMed ID: 34594247
[TBL] [Abstract][Full Text] [Related]
12. Barbiturates and pyrazolopyridines for the treatment of postpartum depression-repurposing of two drug classes.
Horwitz AB; Rubin RT
Front Pharmacol; 2023; 14():1139889. PubMed ID: 36909181
[TBL] [Abstract][Full Text] [Related]
13. A Brexanolone Treatment Program at an Academic Medical Center: Patient Selection, 90-Day Posttreatment Outcomes, and Lessons Learned.
Patterson R; Krohn H; Richardson E; Kimmel M; Meltzer-Brody S
J Acad Consult Liaison Psychiatry; 2022; 63(1):14-22. PubMed ID: 34438099
[TBL] [Abstract][Full Text] [Related]
14. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.
Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A
CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037
[TBL] [Abstract][Full Text] [Related]
15. Treating Postpartum Depression: What Do We Know about Brexanolone?
Ali M; Aamir A; Diwan MN; Awan HA; Ullah I; Irfan M; De Berardis D
Diseases; 2021 Jul; 9(3):. PubMed ID: 34287271
[TBL] [Abstract][Full Text] [Related]
16. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.
Epperson CN; Rubinow DR; Meltzer-Brody S; Deligiannidis KM; Riesenberg R; Krystal AD; Bankole K; Huang MY; Li H; Brown C; Kanes SJ; Lasser R
J Affect Disord; 2023 Jan; 320():353-359. PubMed ID: 36191643
[TBL] [Abstract][Full Text] [Related]
17. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.
Zheng W; Cai DB; Zheng W; Sim K; Ungvari GS; Peng XJ; Ning YP; Wang G; Xiang YT
Psychiatry Res; 2019 Sep; 279():83-89. PubMed ID: 31323375
[TBL] [Abstract][Full Text] [Related]
18. [GABAergic approach of postpartum depression: A translational review of literature].
Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
[TBL] [Abstract][Full Text] [Related]
19. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
